scholarly journals Oxidative stress and radioiodine treatment of differentiated thyroid cancer

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Angelika Buczyńska ◽  
Iwona Sidorkiewicz ◽  
Mariusz Rogucki ◽  
Katarzyna Siewko ◽  
Agnieszka Adamska ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Thyroid Cancer ◽  
Stress Level ◽  
Differentiated Thyroid Cancer ◽  
Radioactive Iodine ◽  
Serum Levels ◽  
Radioiodine Treatment ◽  
Future Health ◽  
Oxidative Stress Level ◽  
One Year

AbstractIt is hypothesized that the oxidative stress level in thyroid cancer patients is additionally upregulated by radioactive iodine (RAI) treatment, that may exert an important impact on future health concerns. In our study, we evaluated the oxidative stress level changes using the measurement of malondialdehyde (MDA) concentration in patients with differentiated thyroid cancer (DTC) undergoing RAI treatment. Considering the results obtained in the study group, the serum levels of MDA in DTC patients were significantly higher compared to the healthy subjects (p < 0.05). The MDA concentration was significantly higher on the third day after RAI (p < 0.001) and significantly lower one year after RAI (p < 0.05) in DTC patients compared to the baseline concentration. Moreover, the redox stabilization after RAI treatment in patients with DTC during a year-long observation was demonstrated. Accordingly, an increased oxidative stress impact on the related biochemical parameters reflecting the health conditions of the DTC patients was determined. Our study showed that increased oxidative stress reflected by MDA measurements in DTC patients is further enhanced by RAI, but this effect is no longer observed one year after the therapy.

scholarly journals Redox parameters in blood of thyroid cancer patients after the radioiodine ablation

2017 ◽  
Vol 32 (4) ◽  
pp. 358-365
Author(s):  
Vera Spasojevic-Tisma ◽  
Milovan Matovic ◽  
Olgica Mihaljevic ◽  
Snezana Zivancevic-Simonovic ◽  
Marija Jeremic ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Thyroid Cancer ◽  
Cancer Patients ◽  
Differentiated Thyroid Cancer ◽  
Radioactive Iodine ◽  
Reduced Glutathione ◽  
Thiobarbituric Acid ◽  
Oxygen Species ◽  
Thiobarbituric Acid Reactive Substances ◽  
Radioiodine Ablation

The radioactive iodine (131I) ablation is a well-accepted treatment modality for differentiated thyroid cancer patients. Unfortunately, the radiation induces the oxidative stress and damages cells and tissues, simultaneously activating the mechanisms of antioxidative defense. Since the mechanisms of those processes are not completely known, we wanted to examine the changes in the most important reactive oxygen species and antioxidative components, as well as their correlation and significance for lipid peroxidation. Our results showed that the level of thiobarbituric acid reactive substances was increased during the first 30 days after the radiotherapy. Among antioxidant components, superoxide dismutase was increased in the 3rd and 30th day; catalase in 7th and reduced glutathione in 3rd and 7th day after the radiotherapy. As regards the prooxidants, the reduction of hydrogen peroxide (H2O2) was recorded in 7th and 30th day, and superoxide anion radical (O?-) was unchanged after the exposure to 131I. These results indicate that differentiated thyroid cancer patients are under constant oxidative stress despite the observed increase in antioxidative and reduction in prooxidative parameters. The understanding of these early processes is important since their progress determines the latter effects of 131I therapy.

scholarly journals Radioiodine treatment of differentiated thyroid cancer despite history of ‘iodine allergy’

2014 ◽  
Vol 2014 ◽  
Author(s):  
Adam R Puchalski ◽  
Inder J Chopra
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Radioactive Iodine ◽  
Ct Scanning ◽  
List Type ◽  
Critical Component ◽  
Radioiodine Treatment ◽  
Radiocontrast Agent ◽  
History Of ◽  
Learning Points

Summary Radioiodine (131I) is a critical component in the treatment of differentiated thyroid cancer. We recently saw a patient with thyroid cancer who was hesitant to take 131I treatment because he had previously encountered an allergic reaction to administration of iodine-containing radiocontrast agent for computed tomography (CT) scanning. We were able to administer 131I treatment after discussion that his anaphylactic reaction was not due to iodine and that radioiodine (131I) treatment is unlikely to cause a reaction in the patient. Learning points An allergy to iodine itself does not exist. When patients claim that they have an ‘iodine allergy’, ask them what substances they are allergic to and what kind of reaction occurred during use of such substances. Radioactive iodine is not a contraindication for patients who claim an ‘allergy to iodine’.

scholarly journals Assessment of different markers of ovarian reserve in women with papillary thyroid cancer treated with radioactive iodine

2021 ◽  
Author(s):  
Agnieszka Adamska ◽  
Paulina Tomczuk-Bobik ◽  
Anna Beata Poplawska-Kita ◽  
Katarzyna Siewko ◽  
Angelika Buczyńska ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Ovarian Reserve ◽  
Radioactive Iodine ◽  
Premenopausal Women ◽  
Serum Levels ◽  
Inhibin B ◽  
Serum Concentrations ◽  
Papillary Thyroid ◽  
One Year

Treatment with radioactive iodine (RAI) in women with differentiated thyroid cancer is associated with decreased serum concentrations of anti-Müllerian hormone (AMH); however, other markers have not been investigated. Therefore, this study aimed to evaluate the effect of RAI on antral follicle count (AFC) and the serum concentration of inhibin B, follicle-stimulating hormone (FSH), and AMH in women with papillary thyroid cancer (PTC) treated with RAI. We examined 25 women at a median age of 33 years treated with a single dose of RAI. We divided the participants into women over (n = 11) and under 35 years of age (n = 14). Serum concentrations of inhibin B, FSH, AMH, and AFC were assessed at baseline and one year after RAI treatment. We found decreased AFC (p = 0.03), serum levels of AMH (p < 0.01), inhibin B (p = 0.03), but not FSH (p = 0.23), one year after RAI treatment in comparison to baseline in the whole group. When we compared serum levels of AMH in younger vs. older women separately, we observed a significant reduction of this hormone’s serum level after RAI treatment in both groups (p < 0.01; p = 0.04, respectively). We concluded that RAI treatment significantly impacts the functional ovarian reserve in premenopausal women with PTC.

Development of the Express Method for Determining the Oxidative Stress Level of the Population

Food Industry ◽  
2018 ◽  
Vol 3 (4) ◽  
Author(s):  
Ekaterina V. Pastushkova ◽  
Olga V. Chugunova ◽  
Leonid S. Volkanin
Keyword(s):  
Oxidative Stress ◽  
Stress Level ◽  
Express Method ◽  
Oxidative Stress Level

scholarly journals The role of Hashimoto thyroiditis in predicting radioiodine ablation efficacy and prognosis of low to intermediate risk differentiated thyroid cancer

2021 ◽  
Author(s):  
Domenico Albano ◽  
Francesco Dondi ◽  
Valentina Zilioli ◽  
Maria Beatrice Panarotto ◽  
Alessandro Galani ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Treatment Response ◽  
Differentiated Thyroid Cancer ◽  
Hashimoto Thyroiditis ◽  
Prognostic Impact ◽  
Intermediate Risk ◽  
Excellent Response ◽  
Radioiodine Ablation ◽  
One Year

Abstract Objective The baseline treatment of differentiated thyroid cancer (DTC) consists of thyroidectomy followed by postoperative risk-adapted radioiodine therapy (RAIT) when indicated. The choice of most appropriate RAI activities to administer with the aim to reach an efficient remnant ablation and reduce the risk of recurrence is yet an open issue and the detection of basal factors that may predict treatment response seems fundamental. The aim of this study was to investigate the potential role of Hashimoto thyroiditis (HT) in predicting 1-year and 5-year treatment response after RAIT and prognosis. Methods We retrospectively included 314 consecutive patients (174 low-risk and 140 intermediate-risk) who received thyroidectomy plus RAIT. One-year and 5-year disease status was evaluated according to 2015 ATA categories response based upon biochemical and structural findings. Results HT was reported histopathologically in 120 patients (38%). DTC patients with concomitant HT received a higher number of RAITs and cumulative RAI activities. Initial RAIT reached an excellent response in 63% after one year and 84% after 5 years. The rate of excellent response one year and 5-year after first RAIT was significantly lower in HT groups, compared to not HT (p < 0.001). Instead, HT did not have a prognostic role considering PFS and OS; while stimulate thyroglobulin (sTg) at ablation was significantly related to survival. Conclusions HT may affect the efficacy of RAIT in low to intermediate risk DTC, particularly reducing the successful rate of excellent response after RAIT. Instead, HT did not have a prognostic impact such as stimulated sTg.

Sign in / Sign up

Export Citation Format

Share Document